Login / Signup

Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.

Lucrezia ColonnaChristopher W PetersonJohn B SchellJudith M CarlsonVictor TkachevMelanie BrownAlison YuSowmya ReddyWilli M ObenzaVeronica NelsonPatricia S PolacinoHeather MackShiu-Lok HuKatie ZeleskiMichelle HoffmanJoe OlveraScott N FurlanHengqi Betty ZhengAgne TaraseviciuteDaniel J HuntKayla BetzJennifer F LaneKeith VogelCharlotte E HotchkissCassie MoatsAudrey BaldessariRobert D MurnaneChristopher EnglishCliff A AstleySolomon WangariBrian AgricolaJoel AhrensNaoto IwayamaAndrew MayLaurence StenslandMeei-Li W HuangKeith R JeromeHans-Peter KiemLeslie S Kean
Published in: Nature communications (2018)
Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, raising the question of whether transplantation can eradicate the HIV reservoir. To test this, we here present a model of allo-HCT in SHIV-infected, cART-suppressed nonhuman primates. We infect rhesus macaques with SHIV-1157ipd3N4, suppress them with cART, then transplant them using MHC-haploidentical allogeneic donors during continuous cART. Transplant results in ~100% myeloid donor chimerism, and up to 100% T-cell chimerism. Between 9 and 47 days post-transplant, terminal analysis shows that while cell-associated SHIV DNA levels are reduced in the blood and in lymphoid organs post-transplant, the SHIV reservoir persists in multiple organs, including the brain. Sorting of donor-vs.-recipient cells reveals that this reservoir resides in recipient cells. Moreover, tetramer analysis indicates a lack of virus-specific donor immunity post-transplant during continuous cART. These results suggest that early post-transplant, allo-HCT is insufficient for recipient reservoir eradication despite high-level donor chimerism and GVHD.
Keyphrases